Clinical trials: CRP
Non-small Cell Lung Cancer
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.
The purpose of this study was to evaluate the major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR of…
- Trial name
- CANOPY-N (NCT03968419)
- Testing
- Canakinumab, Pembrolizumab
- Where
- 29 sites in United States, Belgium and 10 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Rheumatoid
A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis
This study is designed to compare a range of doses of SB-681323 with prednisolone, which has known effects on rheumatoid arthritis patients.
- Trial name
- NCT00134693
- Testing
- Prednisolone, SB-681323
- Where
- 28 sites in Australia, France and 3 more
- Volunteers
- 77 people
- Sponsor
- GlaxoSmithKline
Paroxysmal Atrial Fibrillation
Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation
The purpose of this study is to evaluate whether treatment with ISIS CRP Rx can reduce AF (Atrial Fibrillation) burden (percentage of time spent in AF) in subjects with paroxysmal AF
- Trial name
- ASET (NCT01710852)
- Testing
- ISIS CRP Rx
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Essential Hypertension
Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension
The purpose of this study is to assess which drug is more effective of Ramiprin®(ramipril) and Tritace®(ramipril) in the Treatment of Essential Hypertension
- Trial name
- NCT00366119
- Testing
- Ramipril
- Where
- South Korea
- Volunteers
- 86 people
- Sponsor
- Pacific Pharmaceuticals
Arthritis, Rheumatoid
SB-681323 In Subjects With Rheumatoid Arthritis
The purpose of this research is to find out how effective and safe SB-681323 will be in the treatment of RA when it is added to standard anti-rheumatic treatments.
- Trial name
- NCT00320450
- Testing
- SB-681323
- Where
- 41 sites in Denmark, Germany and 7 more
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Healthy
Determination of Normal Reference Values of CRP, Procalcitonin, and Lactate Levels for the Nanōmix eLab® System
The main objective of this clinical study is to determine the normal reference range of the Nanōmix eLab® (eLab) C-Reactive Protein, Procalcitonin and Lactate Assay.
- Trial name
- NCT03619109
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Nanomix
Red Blood Cell Health, Biological Aging
Effect of Pentadecanoic Acid Supplementation on Red Blood Cell Health and Biological Aging in Healthy Older Adults
This Phase II randomized, double-blind, placebo-controlled, parallel-group study will evaluate the effects of pentadecanoic acid (C15:0) supplementation on red blood cell (RBC) health and predicted biological age in healthy…
- Conditions
- Red Blood Cell Health, Biological Aging, Healthy Aging
- Trial name
- NCT07812792
- Testing
- Pentadecanoic Acid
- Where
- Canada
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- ReCellience15, Inc
Post-cardiac Surgery
Study on CRP Apheresis After Coronary Bypass Surgery
The CABY1 study is conducted open, controlled, randomized and monocentric. The efficacy and tolerability of CRP apheresis in patients undergoing elective primary coronary bypass surgery is investigated.
- Trial name
- CABY1 (NCT04745468)
- Testing
- CRP apheresis
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Pentracor GmbH
Amyotrophic Lateral Sclerosis
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation. Half of participants will receive NP001 and the other half will receive placebo.
- Trial name
- NCT02794857
- Testing
- NP001
- Where
- 22 sites in United States, Canada
- Volunteers
- 138 people
- Sponsor
- Neuraltus Pharmaceuticals, Inc.
Chronic Kidney Diseases, Inflammation
Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition
Patients with chronic kidney disease, who have evidence of systemic inflammation with increased cardiovascular risk, will be enrolled into this trial.
- Trial name
- RESCUE (NCT03926117)
- Testing
- Ziltivekimab
- Where
- 49 sites in United States
- Volunteers
- 264 people
- Sponsor
- Novo Nordisk A/S
Post Prandial Inflammation Markers
Study to Investigate the Efficacy of Digestive Enzymes on Inflammation After a Meal
The primary objective of the study is to assess the efficacy of Digestive Enzyme Blend #2, a digestive enzyme dietary supplement product, on markers indicative of inflammation after a meal.
- Trial name
- NCT01729793
- Testing
- Digestive Enzyme #2
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Enzyme Company
Obesity, Elevated High-sensitivity C-reactive Protein (hsCRP)
A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity
This study is being done to look at the efficacy single and multiple ascending dose study investigating safety, tolerability, pharmacokinetics, food effect and target engagement in healthy adults including a single cohort in…
- Trial name
- NCT07693868
- Testing
- NNC6022-0004
- Where
- Netherlands
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Crohn's Disease
Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )
This is a multi-center study that explores the relationship between recapture of response with escalation to weekly adalimumab and trough adalimumab concentration before escalation in patients experiencing lack of response (LOR).
- Trial name
- PRADA (NCT02896985)
- Where
- 24 sites in Canada
- Volunteers
- 98 people
- Sponsor
- AbbVie
Hypertension
Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)
The study compares the efficacy of an aggressive versus a moderate initial antihypertensive regimen to reduce blood pressure in patients with Stage 2 hypertension.
- Trial name
- NCT00154271
- Testing
- Valsartan, Valsartan HCT
- Volunteers
- 1,677 people
- Sponsor
- Novartis
Healthy Volunteers, C-Reactive Protein
A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)
The main purpose of this study is to evaluate the safety and tolerability of LY5625575 in healthy participants (including Japanese and Chinese) and in participants with high levels of a marker for inflammation (C-reactive…
- Trial name
- NCT07801300
- Testing
- LY5625575
- Where
- 2 sites in United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
End Stage Kidney Disease (ESKD)
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)
This is a phase 1b, partial-blind (Sponsor unblinded), randomized, multicenter, placebo-controlled study. The primary objective of this study is to evaluate the pharmacokinetics (PK) of CSL300 after single and multiple doses in…
- Trial name
- NCT07619820
- Testing
- CSL300
- Where
- China
- Volunteers
- 24 people
- Sponsor
- CSL Behring
Arthritis, Rheumatoid
Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)
This study is designed to compare a range of doses of GW856553 versus placebo on the biomarkers associated with rheumatoid arthritis
- Trial name
- NCT00256919
- Testing
- GW856553
- Where
- 17 sites in Bulgaria, Germany and 3 more
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Chronic Kidney Diseases, Chronic Kidney Insufficiency
A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP
This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney disease…
- Conditions
- Chronic Kidney Diseases, Chronic Kidney Insufficiency, Chronic Renal Diseases, Chronic Renal Insufficiency
- Trial name
- TRANQUILITY (NCT06362759)
- Testing
- TOUR006 - 50 MG, TOUR006 - 25 MG, TOUR006 - 15 MG
- Where
- 38 sites in United States
- Volunteers
- 143 people
- Sponsor
- Tourmaline Bio, Inc., a Novartis Company
Rheumatoid Arthritis
A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA
This study was a Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus DMARD Therapy to that of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and Cytokines in Subjects with Rheumatoid…
- Trial name
- NCT00747214
- Testing
- CRx-102, DMARD Therapy
- Volunteers
- 59 people
- Sponsor
- Zalicus
Juvenile Idiopathic Arthritis
Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis
The primary objective of this study is to evaluate the pharmacokinetics (PK) of olokizumab (OKZ) in patients with polyarticular juvenile idiopathic arthritis aged >2 and <18 years in two doses (64 mg or 48 mg every 4 weeks)…
- Trial name
- NCT07517575
- Testing
- OKZ q4w
- Where
- 14 sites in Russia
- Volunteers
- 71 people
- Sponsor
- R-Pharm International, LLC